Publication Name	World Journal of Clinical Cases
Manuscript ID	70711
Country	Brazil

Received	2021-08-12 01:46
Peer-Review Started	2021-08-12 01:53
To Make the First Decision
Return for Revision	2021-10-20 21:28
Revised	2021-11-13 02:01
Second Decision	2021-12-31 03:38
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-12-31 22:18
Articles in Press	2021-12-31 22:18
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-12-29 23:30
Typeset the Manuscript	2022-01-11 08:54
Publish the Manuscript Online	2022-01-24 08:11

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Rheumatology
Manuscript Type	Letter to the Editor
Article Title	Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us?
Manuscript Source	Invited Manuscript
All Author List	Jucier Gonçalves Júnior and Samuel Katsuyuki Shinjo
ORCID	Author(s) ORCID Number Jucier Gonçalves Júnior http://orcid.org/0000-0001-5077-7959 Samuel Katsuyuki Shinjo http://orcid.org/0000-0002-3682-4517
Funding Agency and Grant Number
Corresponding Author	Jucier Gonçalves Júnior, MD, Academic Research, Division of Rheumatology, São Paulo University, Av. Dr. Arnaldo 3184, 3º Andar-Sala 3131 Cerqueira César, São Paulo 01246-903, Brazil. juciergjunior@hotmail.com
Key Words	Case report; Human immunodeficiency virus; Nemaline myopathy; Rituximab; Rheumatology; Therapy
Core Tip	Rituximab may be a therapeutic possibility for the treatment of Nemaline Myopathies (e.g., human immunodeficiency virus-associated and Monoclonal Gammopathy of Undetermined Significance-associated) because it is less aggressive and has fewer side effects compared to current therapies. Especially in cases of severe visceral involvement. However, the cost and unavailability of therapy can be a limiting factor.
Publish Date	2022-01-24 08:11
Citation	Gonçalves Júnior J, Shinjo SK. Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us? World J Clin Cases 2022; 10(4): 1454-1456
URL	https://www.wjgnet.com/2307-8960/full/v10/i4/1454.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i4.1454

Full Article (PDF)	WJCC-10-1454.pdf
Full Article (Word)	WJCC-10-1454.docx
Manuscript File	70711_Auto_Edited-JRF-Filipodia CL.docx
Answering Reviewers	70711-Answering reviewers.pdf
Audio Core Tip	70711-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	70711-Conflict-of-interest statement.pdf
Copyright License Agreement	70711-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	70711-Language certificate.pdf
Peer-review Report	70711-Peer-review(s).pdf
Scientific Misconduct Check	70711-Bing-Fan JR-2.png
Scientific Editor Work List	70711-Scientific editor work list.pdf